SURPASS-2
Definition
Tirzepatide against semaglutide 1 mg in type 2 diabetes (Frías et al., NEJM 2021): HbA1c −2.30 points against −1.86, and body weight −11.2 kg against −5.7 kg over 40 weeks. The first major head-to-head between the two leaders, at a diabetes dose rather than a weight-management one.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.
Other terms under trial
Where the evidence lives
- SURPASS-2 trial deep-dive
- The full GLP-1 glossary (149 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers